Is Nodal Clipping Beneficial for Node-Positive Breast Cancer Patients Receiving Neoadjuvant Chemotherapy?

[1] Gianni L(2012)Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 13 25-32

[2] Pienkowski T(2020)Pembrolizumab for early triple-negative breast cancer N Engl J Med. 382 810-821

[3] Im YH(2020)Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial Lancet 396 1090-1100

[4] Schmid P(2021)Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis JAMA Surg 156 3467-3474

[5] Cortes J(2016)How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study Ann Surg Oncol. 23 4515-4522

[6] Pusztai L(2020)Selecting node-positive patients for axillary downstaging with neoadjuvant chemotherapy Ann Surg Oncol. 27 725-733

[7] Mittendorf EA(2020)De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study Breast Cancer Res Treat. 180 1455-1461

[8] Zhang H(2013)Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial JAMA. 310 609-618

[9] Barrios CH(2013)Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study Lancet Oncol. 14 258-264

[10] Samiei S(2015)Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study J Clin Oncol. 33 343-352

[1] Gianni L(2012)Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 13 25-32

[2] Pienkowski T(2020)Pembrolizumab for early triple-negative breast cancer N Engl J Med. 382 810-821

[3] Im YH(2020)Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial Lancet 396 1090-1100

[4] Schmid P(2021)Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis JAMA Surg 156 3467-3474

[5] Cortes J(2016)How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study Ann Surg Oncol. 23 4515-4522

[6] Pusztai L(2020)Selecting node-positive patients for axillary downstaging with neoadjuvant chemotherapy Ann Surg Oncol. 27 725-733

[7] Mittendorf EA(2020)De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study Breast Cancer Res Treat. 180 1455-1461

[8] Zhang H(2013)Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial JAMA. 310 609-618

[9] Barrios CH(2013)Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study Lancet Oncol. 14 258-264

[10] Samiei S(2015)Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study J Clin Oncol. 33 343-352